KEROS THERAPEUTICS INC (KROS) — insider trading
Health Care · NASDAQ
KEROS THERAPEUTICS INC (KROS) has 25 reported SEC Form 4 insider transactions in our data, including 5 open-market purchases and 8 open-market sales among the most recent 25 (latest 2026-08-18).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-18 | Newton Charles W. | Director | Open-market sale | 551 | $10.30 | $5.7K | Form 4 |
| 2026-08-18 | Cho Esther | Officer (Chief Legal Officer) | Open-market sale | 4,485 | $10.29 | $46.2K | Form 4 |
| 2026-08-18 | Lerner Lorena Raquel | Officer (Chief Scientific Officer) | Open-market sale | 3,568 | $10.29 | $36.7K | Form 4 |
| 2026-08-18 | Tanini Annita | Officer (Corp. Controller & VP, Finance) | Open-market sale | 1,224 | $10.29 | $12.6K | Form 4 |
| 2026-08-17 | BIENAIME JEAN JACQUES | Director | Open-market purchase | 1,000 | $10.27 | $10.3K | Form 4 |
| 2026-07-15 | BIENAIME JEAN JACQUES | Director | Open-market purchase | 1,000 | $10.61 | $10.6K | Form 4 |
| 2026-07-01 | Prener Anne | Director | Grant / award / vesting (derivative) | 14,870 | — | $0 | Form 4 |
| 2026-07-01 | Prener Anne | Director | Grant / award / vesting | 13,786 | — | $0 | Form 4 |
| 2026-06-15 | BIENAIME JEAN JACQUES | Director | Open-market purchase | 1,000 | $10.19 | $10.2K | Form 4 |
| 2026-06-11 | Newton Charles W. | Director | Open-market sale | 550 | $10.04 | $5.5K | Form 4 |
| 2026-06-04 | Knowles Julius | Director | Open-market sale | 2,625 | $10.73 | $28.2K | Form 4 |
| 2026-06-04 | Farzan Nima | Director | Open-market sale | 2,625 | $10.73 | $28.2K | Form 4 |
| 2026-06-04 | Seth Alpna | Director | Open-market sale | 2,625 | $10.72 | $28.1K | Form 4 |
| 2026-06-03 | Knowles Julius | Director | Grant / award / vesting (derivative) | 7,433 | — | $0 | Form 4 |
| 2026-06-03 | Knowles Julius | Director | Grant / award / vesting | 7,142 | — | $0 | Form 4 |
| 2026-06-03 | BIENAIME JEAN JACQUES | Director | Grant / award / vesting (derivative) | 7,433 | — | $0 | Form 4 |
| 2026-06-03 | BIENAIME JEAN JACQUES | Director | Grant / award / vesting | 7,142 | — | $0 | Form 4 |
| 2026-06-03 | Farzan Nima | Director | Grant / award / vesting (derivative) | 7,433 | — | $0 | Form 4 |
| 2026-06-03 | Farzan Nima | Director | Grant / award / vesting | 7,142 | — | $0 | Form 4 |
| 2026-06-03 | GRAY MARY ANN | Director | Grant / award / vesting (derivative) | 7,433 | — | $0 | Form 4 |
| 2026-06-03 | GRAY MARY ANN | Director | Grant / award / vesting | 7,142 | — | $0 | Form 4 |
| 2026-06-03 | Seth Alpna | Director | Grant / award / vesting (derivative) | 7,433 | — | $0 | Form 4 |
| 2026-06-03 | Seth Alpna | Director | Grant / award / vesting | 7,142 | — | $0 | Form 4 |
| 2026-05-15 | BIENAIME JEAN JACQUES | Director | Open-market purchase | 1,000 | $10.58 | $10.6K | Form 4 |
| 2026-04-15 | BIENAIME JEAN JACQUES | Director | Open-market purchase | 1,000 | $11.70 | $11.7K | Form 4 |
Ask the chat about KROS's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: KEROS THERAPEUTICS INC (KROS).
Last updated 2026-08-18 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.